Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2025 · 10-Q
Revenue$222.20M$222.20M−26.0% vs Q1 2024 Net Income$68.00M$68.00M+655.6% vs Q1 2024 EPS Diluted$1.19$1.19+600.0% vs Q1 2024 Operating Income$49,900,000+25.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Free Cash Flowderived-$14,800,000N/M Margins · derivedOperating margin22.5%+9.2 pt vs Q1 2024
Net margin30.6%+27.6 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end